Aged
Aged, 80 and over
Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Membrane Glycoproteins
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
/ radiotherapy
Organometallic Compounds
Positron Emission Tomography Computed Tomography
/ methods
Prostatectomy
/ methods
Prostatic Neoplasms
/ diagnostic imaging
Radiopharmaceuticals
Radiotherapy, Image-Guided
Retrospective Studies
Treatment Outcome
Metastasis-directed therapy
Oligometastatic
PSMA
Prostate cancer
Radiotherapy
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
09
06
2018
accepted:
21
02
2019
pubmed:
3
3
2019
medline:
20
2
2020
entrez:
3
3
2019
Statut:
ppublish
Résumé
The aim of this communication was to assess the efficacy of directed oligometastatic radiotherapy (RT) based on This is a retrospective analysis of a monocentric cohort of PCa patients diagnosed with oligometastatic disease on 20 patients met the inclusion criteria. Median PSA value: 1.4 ng/ml (IQR, 0.3-2.3 ng/ml). A total of 30 PSMA-positive lesions were treated: 18 lymph nodes (60%), nine bone (30%) and three visceral lesions (10%). Median follow-up was 15 months (range 4-33 months). Biochemical response at 1 and 4 months was found in 3/20 patients (15%) and 14/20 (70%), respectively. BCR-free survival rate at 1 year was 79% and 53% at 2 years. ADT-free survival at 2 years was 74%. This retrospective study suggests that metastasis-directed RT based on
Identifiants
pubmed: 30824985
doi: 10.1007/s00345-019-02701-1
pii: 10.1007/s00345-019-02701-1
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Membrane Glycoproteins
0
Organometallic Compounds
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1535-1542Références
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 2017(67):7–30
doi: 10.3322/caac.21387
van den Bergh RC, van Casteren NJ, van den Broeck T et al (2016) Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol 69:802–820
doi: 10.1016/j.eururo.2015.11.023
Choueiri TK, Dreicer R, Paciorek A et al (2008) A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 179(3):906–910
doi: 10.1016/j.juro.2007.10.059
Ost P, Decaestecker K, Lambert B et al (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74:297–305
doi: 10.1002/pros.22750
Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28–e37
doi: 10.1016/S1470-2045(12)70510-7
Schweizer MT, Zhou XC, Wang H et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24:2881–2886
doi: 10.1093/annonc/mdt335
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10
doi: 10.1200/JCO.1995.13.1.8
Salah S, Watanabe K, Welter S et al (2012) Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol 23:2649–2655
doi: 10.1093/annonc/mds100
Staren ED, Salerno C, Rongione A et al (1992) Pulmonary resection for metastatic breast cancer. Arch Surg 127:1282–1284
doi: 10.1001/archsurg.1992.01420110024006
Castellucci Paolo, Fuccio Chiara, Nanni Cristina et al (2009) Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 50:1394–1400
doi: 10.2967/jnumed.108.061507
Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–936
pubmed: 2449118
Eder M, Schafer M, Bauder-Wust U et al (2012) (68) Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697
doi: 10.1021/bc200279b
Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68 Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 40(4):486–495
doi: 10.1007/s00259-012-2298-2
Schwenck J, Rempp H, Reischl G et al (2017) Comparison of 68 Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44:92–101
doi: 10.1007/s00259-016-3490-6
Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K et al (2008) The detection rate of (11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23
doi: 10.1007/s00259-007-0581-4
Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937
doi: 10.1016/j.eururo.2016.06.021
Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G (2017) Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus. 3(6):538–544
doi: 10.1016/j.euf.2017.07.006
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453
doi: 10.1200/JCO.2017.75.4853
Wimana Z, Artigas C, Flamen P, Ghanem G (2015) One-step radiosynthesis of 68 Ga-DKFZ-PSMA at room temperature. Eur J Nucl Med Mol Imaging 42(Suppl 1):S173
Lecouvet FE, Geukens D, Stainier A, Jamar F et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25(22):3281–3287
doi: 10.1200/JCO.2006.09.2940
Aoun F, Kourie HR, Artigas C, Roumeguere T (2015) Next revolution in molecular theranostics: personalized medicine for urologic cancers. Future Oncol 11:2205–2219
doi: 10.2217/fon.15.104
Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642
doi: 10.1016/j.eururo.2016.08.002
Hershman DL, Unger JM, Wright JD et al (2016) Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2:453–461
doi: 10.1001/jamaoncol.2015.4655
Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
pubmed: 9815541
Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334
doi: 10.1016/S0090-4295(96)00184-7
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192–3198
pubmed: 10397265
Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P (2016) Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 43(1):195–196
doi: 10.1007/s00259-015-3236-x
Artigas C, Otte F-X, Lemort M, van Velthoven R, Flamen P (2017) Vertebral hemangioma mimicking bone metastasis in 68 Ga-PSMA ligand PET/CT. Clin Nucl Med 42(5):368–370
doi: 10.1097/RLU.0000000000001631
Albisinni S, Artigas C, Aoun F et al (2017) Clinical impact of (68) Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int 120:197–203
doi: 10.1111/bju.13739
Calais J, Czernin J, Cao M et al (2018) 68 Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 59(2):230–237
doi: 10.2967/jnumed.117.201749
Han S, Woo S, Kim YJ, Suh CH (2018) Impact of (68) Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74(2):179–190
doi: 10.1016/j.eururo.2018.03.030
Decaestecker K, De Meerleer G, Lambert B, Delrue L et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135
doi: 10.1186/1748-717X-9-135
Murphy DG, Sweeney CJ, Tombal B (2017) "Gotta Catch 'em All", or Do We? Pokemet approach to metastatic prostate cancer. Eur Urol 72(1):1–3
doi: 10.1016/j.eururo.2017.02.036
Goonewardene S, Alsheikh M (2018) The role of PSMA PET scans in salvage therapy planning. World J Urol 36(3):503–504
doi: 10.1007/s00345-017-2149-7
Guler OC, Engels B, Onal C, Everaert H et al (2018) The feasibility of prostate-specific membrane antigen positron emission tomography (PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin Transl Oncol 20(4):484–490
doi: 10.1007/s12094-017-1736-9
Schmidt-Hegemann NS, Fendler WP, Ilhan H et al (2018) Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol 13(1):37
doi: 10.1186/s13014-018-0983-4
Emmett L, van Leeuwen PJ, Nandurkar R et al (2017) Treatment outcomes from 68 Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med 58:1972–1976
doi: 10.2967/jnumed.117.196683
Yaxley JW, Dagher J, Delahunt B et al (2018) Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 36(1):15–20
doi: 10.1007/s00345-017-2119-0
Frees S, Akamatsu S, Bidnur S, Khalaf D et al (2018) The impact of time to metastasis on overall survival in patients with prostate cancer. World J Urol 36(7):1039–1046
doi: 10.1007/s00345-018-2236-4